Pharmacology, Toxicology and Pharmaceutical Science
Pharmacokinetics
100%
Negative Syndrome
92%
Positive Syndrome
92%
Placebo
83%
Pharmacodynamic Modeling
79%
Receptor
76%
Typical Antipsychotic
76%
Antipsychotic
45%
Olanzapine
43%
Pharmacodynamics
41%
4 (para chlorophenyl) 1 [3 (para fluorobenzoyl)propyl] 4 piperidinol
38%
Dopamine Receptor D2
36%
Paliperidone
34%
Risperidone
31%
Pharmacotherapy
27%
Atypical Antipsychotics
19%
Schizophrenia Clinical Trial
15%
Extrapyramidal Symptoms
15%
Drug Development
14%
Clinical Trial
14%
PK/PD Models
14%
Ziprasidone
11%
Catalepsy
11%
Pharmacokinetics
11%
Pharmacodynamic Parameter
6%
Dopamine Receptor
5%
Drug Concentration
5%
Neuroscience
Dementia Praecox
70%
Receptor Occupancy
70%
Pharmacokinetics
67%
Positive Syndrome
54%
Negative Syndrome
54%
Placebo
52%
Typical Antipsychotic
51%
Paliperidone
42%
Risperidone
39%
Dopamine Receptor D2
36%
Haloperidol
23%
Neural Network
22%
Atypical Antipsychotic
17%
Olanzapine
15%
5-HT2A Receptor
15%
Catalepsy
11%
Treatment of Schizophrenia
11%
Extrapyramidal Symptoms
11%
Pharmacokinetics
11%
Striatum
9%
In Vitro
8%
Receptor Binding
7%
Ziprasidone
7%
Keyphrases
Pharmacokinetic-pharmacodynamic Modeling
37%
Negative Syndrome
34%
Schizophrenia
23%
Patients with Schizophrenia
22%
Antipsychotics
17%
Paliperidone
14%
Haloperidol
14%
Modeling Approach
12%
Neural Network
12%
Individual-based Simulation
12%
Rating Scales
12%
Drug Effects
12%
Theoretical Biology
11%
Evolution of Sex
11%
Clinical Utility
11%
Evolutionary Learning
11%
Evolutionary Biology
11%
Network Simulation
11%
Project Evolution
11%
Sex Determination Mechanism
11%
Sex Ratio Selection
11%
Population Pharmacokinetics
11%
Drug Treatment
11%
Catalepsy
11%
Dropout Pattern
11%
Dopamine D2 Receptor Occupancy
11%
PKPD Modeling
11%
Placebo Treatment
11%
Bulb Mite
11%
Neural Network Model
11%
Social Learning
11%
Dropout
9%
Koff
8%
Placebo Effect
7%
Receptor Occupancy
7%
Sex-determining System
6%
D2 Receptor
6%
Extrapyramidal Side Effects
6%
Dropout Rate
5%
Rescorla-Wagner
5%
Emax
5%
Individual Learning
5%
